In a study designed to identify the relevant cost per number needed to treat for the 2 biological disease-modifying antirheumatic drugs tocilizumab (TCZ) and abatacept, researchers determined that TCZ had a higher efficacy.
In a study designed to identify the relevant cost per number needed to treat (NNT) for the 2 biological disease-modifying antirheumatic drugs tocilizumab (TCZ) and abatacept (ABT), researchers determined that TCZ had a higher efficacy. The results were published in ClinicoEconomics and Outcomes Research.
The authors used clinical data from a Technology Appraisal Guidance published by the National Institute for Health and Care Excellence in January 2016 to estimate the efficacy and treatment costs associated with the use of TCZ plus methotrexate (Mtx) versus ABT plus Mtx when treating patients with rheumatoid arthritis (RA) who were previously treated with Mtx.
In this study, the NNT “represents the number of patients who needed to be treated with TCZ plus Mtx or with ABT plus Mtx” compared with conventional disease-modifying antirheumatic drugs, such as Mtx alone, “to obtain a positive patient response.” Efficacy was measured based on response criteria from the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR).
Both ABT and TCZ can be administered subcutaneously (sc) or intravenously (iv). The research found that the lost cost of treatment was ABT (sc) plus Mtx (€6398.98 or $7450.01) and the highest cost of treatment was ABT (iv) plus Mtx (€7342.66 or $8549.61).
The researchers found that when they calculated mean cost per NNT using ACR response criteria that TCZ (sc) had the lowest cost per NNT. Interestingly, TCZ (iv) may have had higher costs of administration and monitoring but it had lower mean costs per NNT compared to both forms of ABT. Using EULAR criteria also found TCZ (sc) to be the best therapeutic followed by TCZ (iv).
Based on their findings, the authors determined that TCZ, in both forms, is a more cost-effective option than both forms of ABT when it comes to treating patients with RA who were previously treated with Mtx.
“The findings of this study should encourage the undertaking of future clinical observational and real-world studies aimed at promoting a more efficient use of biological therapies in the treatment of RA,” the authors concluded.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More